1. Home
  2. Vol 54, No 4 (2022)
  3. Al Ali

Long-Term Use of Omeprazole: Effect on Haematological and Biochemical Parameters

Hadeel S. Al Ali, Azza Sajid Jabbar, Nadheerah F. Neamah, Nawal Khalil Ibrahim

Abstract


Background: Long-term use of proton pump inhibitors (PPIs) is believed to have various potential adverse events. Omeprazole is a part of PPIs most commonly prescribed worldwide; it irreversibly binds to H+-K+ ATPase enzyme system in the gastric parietal cells to reduce secretion of H+ ions into the lumen of stomach. The main objective of the current work is to assess the adverse effects of omeprazole medication on certain haematological and biochemical parameters in patients who were on treatment for one year and more. Methods: We conducted a comparative cross-sectional study between October 2021 and March 2022. A total of 90 participants of both sexes were enrolled in this study, aged between 25-58 years. The participants were categorized into two groups: 40 patients on long-term omeprazole medication (40 mg) as a patients group and 50 healthy subjects as a healthy group who did not use omeprazole. Complete blood count and biochemical parameters were measured for both groups. Results: Patients of a group 1 had remarkable significant reductions in the number of red blood cells (RBCs) (p<0.001) and the indices. Omeprazole elevated the cholesterol level (p<0.001) and triglyceride (p<0.001) as well as low-density lipoprotein (p<0.01). However, no impact was found with high-density lipoprotein (HDL) (p>0.05). Alkaline phosphatase (ALKP) (p<0.001) and aspartate aminotransferase (ASAT) (p<0.01) levels were elevated in long-term patients treated with omeprazole. In contrast, no significant change was found in the level of alanine aminotransferase (ALAT) (p>0.05). Creatinine level (p<0.001) and nitrogen blood urea (p<0.0001) were significantly increased in patients group treated with omeprazole medication. The results also showed that group 1 had a high significant decline in serum ferritin (p<0.0001), vitamin D3 (p<0.01) and calcium levels (p<0.001) than that of healthy group. Conclusion: Prolonged use of omeprazole might result in adverse effect on hematological profile, particularly RBCs and their indices leading to develop anemia in patients on this medication. Furthermore, it might result in disturbances in biochemical profile, levels of minerals and vitamins as consequences of affected absorption.

Keywords


Omeprazole; blood count; hypocalcemia; vitamin D; kidney function; cholesterol; triglyceride

References


Shin JM, Sachs G. Pharmacology of proton pump inhibitors. Curr Gastroenterol Rep. 2008;10(6):528-34.

Shin JM, Munson K, Vagin O, Sachs G. The gastric HK-ATPase: structure, function, and inhibition. Pflügers Archiv-European J Physiol. 2009;457(3):609-22.

Kinoshita Y, Ishimura N, Ishihara S. Advantages and disadvantages of long-term proton pump inhibitor use. J Neurogastroenterol Motility. 2018;24(2):182.

Galdo JA. Long-term consequences of chronic proton pump inhibitor use. US Pharm. 2013;38(12):38-42.

Sharma N, Chau WY, Dobruskin L. Effect of long-term proton pump inhibitor therapy on hemoglobin and serum iron levels after sleeve gastrectomy. Surgery for Obesity Related Diseases. 2019;15(10):1682-9.

Shikata T, Sasaki N, Ueda M, et al. Use of proton pump inhibitors is associated with anemia in cardiovascular outpatients. Circulation. 2014:CJ-14-0582.

Kaczmarczyk O, Przybylska-Feluś M, Piątek-Guziewicz A, et al. Effect of long-term proton pump inhibitor therapy on complete blood count parameters and selected trace elements: a pilot study. Polish Archives of Internal Medicine. 2020;130(3).

Sarzynski E, Puttarajappa C, Xie Y, Grover M, Laird-Fick H. Association between proton pump inhibitor use and anemia: a retrospective cohort study. Digestive Diseases Sciences. 2011;56(8):2349-53.

Imai R, Higuchi T, Morimoto M, Koyamada R, Okada S. Iron deficiency anemia due to the long-term use of a proton pump inhibitor. Internal Medicine. 2018;57(6):899-901.

Krieg L, Milstein O, Krebs P, Xia Y, Beutler B, Du X. Mutation of the gastric hydrogen-potassium ATPase alpha subunit causes iron-deficiency anemia in mice. Blood. 2011;118(24):6418-25.

McColl KE. Effect of proton pump inhibitors on vitamins and iron. Am J Gastroenterol. 2009;104:S5-S9.

Alkhalaylah AA, Hayajneh MM, Hijazeen SI, Alqhewii TA, Haddad ER, Alkhatib AJ. Study the overprescription of proton pump inhibitors and their relation with recurrent community aquired infections in outpatient refilled prescriptions of chronic diseases patients. Eur Sci J. 2016;12(6).

Ribeiro RHT, Ribeiro FA, Silva RPM, Bortolini MJS, Garrote-Filho MdS, Penha-Silva N. Depression, hematologic parameters, and blood levels of vitamin B12 in patients with laryngopharyngeal reflux under use of proton pump inhibitors. Clin Med Insights: Ear, Nose and Throat. 2019;12:1-7.

Sun S, Ye W, Zhao R, et al. Proton pump inhibitor therapy does not affect prognosis of cirrhosis patients with acute decompensation and acute-on-chronic liver failure: A single-center prospective study. Frontiers in Medicine. 2021;8.

Mukherjee S, Jana T, Pan J-J. Adverse effects of proton pump inhibitors on platelet count: a case report and review of the literature. Case Reports Gastrointestinal Medicine. 2018;2018.

Dotan E, Katz R, Bratcher J, et al. The prevalence of pantoprazole associated thrombocytopenia in a community hospital. Expert Opinion on Pharmacotherapy. 2007;8(13):2025-8.

Binnetoğlu E, Akbal E, Şen H, et al. Pantoprazole-induced thrombocytopenia in patients with upper gastrointestinal bleeding. Platelets. 2015;26(1):10-2.

Bijvelds MJ, Bronsveld I, Havinga R, Sinaasappel M, de Jonge HR, Verkade HJ. Fat absorption in cystic fibrosis mice is impeded by defective lipolysis and post-lipolytic events. Am J Physiol-Gastrointestinal Liver Physiol. 2005;288(4):G646-G653.

Namazi M, Sharifian M. The potential anti‐xanthoma and anti‐atherosclerotic effects of proton pump inhibitors. Clin Pharm Ther. 2008;33(6):579-80.

Cronican AA, Fitz NF, Pham T, et al. Proton pump inhibitor lansoprazole is a nuclear liver X receptor agonist. Biochemical Pharmacology. 2010;79(9):1310-6.

Mélo SKM, Santiago TA, de Lima Duarte T, et al. A proton-pump inhibitor modifies the concentration of digestion biomarkers in healthy horses. J Equine Veterinary Science. 2014;34(11-12):1318-23.

Aamir K, Arain AA, Tunio AG, Rasheed K, Soomro UA, Memon RA. Do ppis affect serum lipids? A pilot study in rabbit model. Indo Am J Pharm Sci. 2019;6(2):3060-3.

Abdullah E, Dhiaa S, Saleh K, Merkhan M. Effect of esomeprazole on lipid profile in patients with peptic ulcer. Pharmacia. 2021;68:613.

Wakabayashi T, Hosohata K, Oyama S, et al. Association between a low dose of proton pump inhibitors and kidney function decline in elderly hypertensive patients: a retrospective observational study. J Int Med Res. 2021;49(4):1-8.

Hardy P, Sechet A, Hottelart C, et al. Inhibition of gastric secretion by omeprazole and efficiency of calcium carbonate on the control of hyperphosphatemia in patients on chronic hemodialysis. Artificial Organs. 1998;22(7):569-73.

Graziani G, Badalamenti S, Como G, et al. Calcium and phosphate plasma levels in dialysis patients after dietary Ca-P overload. Nephron. 2002;91(3):474-9.

O’Connell MB, Madden DM, Murray AM, Heaney RP, Kerzner LJ. Effects of proton pump inhibitors on calcium carbonate absorption in women: a randomized crossover trial. Am J Med. 2005;118(7):778-81.

Liamis G, Milionis HJ, Elisaf M. A review of drug-induced hypocalcemia. J Bone Mineral Metabolism. 2009;27(6):635-42.

Milman S, Epstein EJ. Proton pump inhibitor-induced hypocalcemic seizure in a patient with hypoparathyroidism. Endocrine Practice. 2011;17(1):104-7.

Perazella MA. Proton pump inhibitors and hypomagnesemia: a rare but serious complication. Kidney Int. 2013;83(4):553-6.

Toh JWT, Ong E, Wilson R. Hypomagnesaemia associated with long-term use of proton pump inhibitors. Gastroenterol Report. 2015;3(3):243-53.

William JH, Danziger J. Magnesium deficiency and proton‐pump inhibitor use: a clinical review. J Clin Pharmacol. 2016;56(6):660-8.

Cundy T, Dissanayake A. Severe hypomagnesaemia in long‐term users of proton‐pump inhibitors. Clin Endocrinol. 2008;69(2):338-41.

Pettersson J, Hindorf U, Persson P, et al. Muscular exercise can cause highly pathological liver function tests in healthy men. British J Clin Pharmacol. 2008;65(2):253-9.

ElMahdy MF, ALMATER JM. Omeprazole induced increase in liver markers-a case report. J Clin Diag Res. 2019;13(10).

Avinash A, Patil N, Kunder SK, et al. A retrospective study to assess the effect of proton pump inhibitors on renal profile in a south indian hospital. J Clin Diag Res. 2017;11(4):FC09-FC12.

Sowjanya G, Amulya K, Priyanka R, et al. A prospective observational study on the association of the renal disease with the use of proton pump inhibitors in a tertiary care hospital. Indian J Pharm Pract. 2019;12(2):97.

Prakash J, Gupta T, Prakash S, Rathore S. Acute kidney injury in patients with human immunodeficiency virus infection. Indian J Nephrol. 2015;25(2):86.

Autier P, Boniol M, Pizot C, Mullie P. Vitamin D status and ill health: a systematic review. Lancet Diab Endocrinol. 2014;2(1):76-89.

Francis R, Aspray T, Fraser W, et al. Vitamin D and bone health: a practical clinical guideline for patient management. National Osteoporosis Society. 2013;1.

Wagner SC. Proton pump inhibitors and bone health: What the orthopaedic surgeon needs to know. JBJS Reviews. 2018;6(12):e6.

Yu L-Y, Sun L-N, Zhang X-H, et al. A review of the novel application and potential adverse effects of proton pump inhibitors. Advances in Therapy. 2017;34(5):1070-86.

Xu J, Cheng T, Feng H, Pavlos N, Zheng MH. Structure and function of V-ATPases in osteoclasts: potential therapeutic targets for the treatment of osteolysis. Histology Histopathol. 2007:443-54.

Yang Y-X. Chronic proton pump inihibitor therapy and calcium metabolism. Current Gastroenterol Reports. 2012;14(6):473-9.

Brisebois S, Merati A, Giliberto JP. Proton pump inhibitors: Review of reported risks and controversies. Laryngoscope investigative otolaryngology. 2018;3(6):457-62.

Jo Y, Park E, Ahn SB, et al. A proton pump inhibitor’s effect on bone metabolism mediated by osteoclast action in old age: a prospective randomized study. Gut liver. 2015;9(5):607.

Roodman GD. Cell biology of the osteoclast. Experimental hematology. 1999;27(8):1229-41.

Teramura-Grönblad M, Hosia-Randell H, Muurinen S, Pitkala K. Use of proton-pump inhibitors and their associated risks among frail elderly nursing home residents. Scandinavian journal of primary health care. 2010;28(3):154-9.

Qorraj-Bytyqi H, Hoxha R, Sadiku S, et al. Proton pump inhibitors intake and iron and vitamin B12 status: a prospective comparative study with a follow up of 12 months. Open Access Macedonian J Med. 2018;6(3):442.

Koop H, Bachem MG. Serum iron, ferritin, and vitamin B12 during prolonged omeprazole therapy. J Clin Gastroenterol. 1992;14(4):288-92.


Full Text: PDF

Refbacks

  • There are currently no refbacks.